Markets
Breville, Catapult and SiteMinder: Global growth draws broker buy ratings
Breville, Catapult Sports and SiteMinder have each won a broker buy rating as they expand internationally and sell more to existing customers. Their fiscal 2026 results show revenue growth across all three businesses, but different levels of progress o...
Ralph Lauren Stock Holds at Premium Valuation as Cash Generation Remains Steady
Ralph Lauren shares trade near intrinsic value after five-year surge of 248.6%, with investors weighing the fashion house's ability to sustain cash flows against a current price of $375.27 per share....
Grain Funds Post Mixed Session as Soybean Fund Extends Decline
The SOYB soybean fund fell 0.51% to US$27.33 on Tuesday, marking its second consecutive decline, while wheat dropped 0.74% and corn edged marginally higher in quiet trading ahead of key planting season developments....
AT&T Faces Mixed Analyst Ratings as Stock Declines Ahead of Earnings Report
Investment analysts issued divergent ratings on AT&T in October 2026, with Sanford C. Bernstein downgrading the stock amid competitive concerns while KeyCorp maintained its optimistic outlook. The telecommunications giant's shares have declined nearly ...
21 West Wealth Management Reduces Vanguard Intermediate-Term Corporate Bond ETF Holdings by 61.6%
21 West Wealth Management LLC cut its position in Vanguard Intermediate-Term Corporate Bond ETF by 61.6% during the third quarter, reducing its stake to 21,957 shares worth $1.7 million, according to a recent SEC filing....
iShares Core S&P U.S. Value ETF Announces $0.49 Quarterly Dividend, Up 9% From Previous Quarter
BlackRock's IUSV will distribute a quarterly dividend of $0.4911 per share on September 18th to shareholders of record as of September 15th, marking a 9% increase from the previous quarter's payout of $0.45....
Bausch Health Shares See 36% Surge in Trading Activity Amid Analyst Upgrades
Bausch Health Companies experienced unusually high trading volume on Monday, with 3.48 million shares changing hands—a 36% increase from typical levels—as analysts upgraded their outlook on the pharmaceutical company's prospects....
